Serum Uric Acid, Influence of Sacubitril/Valsartan, and Cardiovascular Outcomes in Heart Failure with Preserved Ejection Fraction: PARAGON-HF

Senthil Selvaraj, Brian L Claggett, Marc A Pfeffer, Akshay S Desai, Finnian R McCausland, Martina M McGrath, Inder S Anand, Dirk J van van Veldhuisen, Lars Kober, Stefan Janssens, John G F Cleland, Burkert Pieske, Jean L Rouleau, Michael R Zile, Victor C Shi, Martin P Lefkowitz, John J V McMurray, Scott D Solomon
European Journal of Heart Failure 2020 August 25

AIMS: To determine the prognostic value of serum uric acid (SUA) on outcomes in heart failure with preserved ejection fraction (HFpEF), and whether sacubitril/valsartan reduces SUA and SUA-related therapies.

METHODS AND RESULTS: We analyzed 4795 participants from PARAGON-HF. We related baseline hyperuricemia (using assay definitions) to the primary outcome (CV death and total HF hospitalization). Between baseline and 4 months, we assessed the association between changes in SUA and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) and other cardiac biomarkers. We simultaneously adjusted for baseline and time-updated SUA to determine whether lowering SUA was associated with clinical benefit. Average age was 73 ± 8 years and 52% were women. After multivariable adjustment, hyperuricemia was associated with increased risk for the primary outcome (rate ratio 1.61, 95%CI 1.37, 1.90). The treatment effect of sacubitril/valsartan for the primary endpoint was not significantly modified by hyperuricemia (p-interaction = 0.14). Sacubitril/valsartan reduced SUA -0.38 mg/dL (95%CI: -0.45, -0.31) compared with valsartan at 4 months, with greater effect in those with elevated SUA vs. normal SUA (-0.51 vs. -0.32 mg/dL) (p-interaction = 0.031). Sacubitril/valsartan reduced the odds of initiating SUA-related treatments by 32% during follow-up (p < 0.001). After multivariable adjustment, change in SUA was inversely associated with change in KCCQ-OSS and directly associated with high-sensitivity Troponin T (p < 0.05). Time-updated SUA was a stronger predictor of adverse outcomes than baseline SUA.

CONCLUSIONS: SUA independently predicted adverse outcomes in HFpEF. Sacubitril/valsartan reduced SUA and related therapy initiation compared to valsartan. Reducing SUA was associated with improved outcomes.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Trending Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"